Turning Point Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Turning Point Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-0.4%
Buyback Yield
| Total Shareholder Yield | -0.4% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Bristol Myers U.S., German antitrust filings for Turning Point expected very soon - report
Jul 21We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth
Mar 23
Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth
Dec 06The Take On Turning Point Therapeutics
Dec 03Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts
Aug 15Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business
Aug 04Turning Point Therapeutics gets FDA orphan drug status for TPX-0022 in gastric cancer
Jun 17Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 08Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?
Feb 26Turning Point Therapeutics' repotrectinib shows promising results in lung cancer study
Jan 29Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher
Jan 22
We're Not Worried About Turning Point Therapeutics' (NASDAQ:TPTX) Cash Burn
Jan 13Turning Point Therapeutics: An Emerging Growth Story In TKI-Resistant Cancers
Dec 28Is Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Trading At A 48% Discount?
Dec 15Turning Point Therapeutics' lead candidate nabs accelerated review for lung cancer
Dec 08Turning Point Therapeutics EPS beats by $0.12, beats on revenue
Nov 12Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if TPTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TPTX's dividend payments have been increasing.
Dividend Yield vs Market
| Turning Point Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (TPTX) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Biotechs) | 2.3% |
| Analyst forecast (TPTX) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate TPTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TPTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate TPTX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as TPTX has not reported any payouts.